Closing the Ring

Reflecting work in the Proulx Lab

Published here November 13, 2026

Head-to-Tail Peptide Cyclization of N‑Aryl Peptide Hydrazides

Ellen J. T. Warner, Karlee C. McKinney, Quibria A. E. Guthrie, Briley A. Humphrey, and Caroline Proulx

Organic Letters XXXX, XXX, XXX−XXX. https://doi.org/10.1021/acs.orglett.6c04383

View Original Publication


Head-to-tail peptide macrocyclization via hydrazone and oxime ligations is attractive in principle: these reactions are chemoselective, water-compatible, and produce linkages that can be elaborated post-cyclization. In practice, intramolecular reactions between α-oxo aldehydes or ketones and α-nucleophiles on peptide substrates have remained scarce, with few head-to-tail examples demonstrated. Prior methods also left little room to vary the side chain at the ligation site, keeping the method from reaching general utility.

Researchers in the Proulx Group at North Carolina State University, published in Organic Letters, reasoned that N-aryl peptide hydrazides could serve as bifunctional precursors and bypass those constraints. N-aryl amino acids are incorporated via standard peptoid submonomer procedures, and the C-terminal hydrazide is easily introduced during solid-phase assembly. After cleavage, the unprotected peptide is dissolved in phosphate buffer at pH 7 under O2 atmosphere: oxygen oxidizes the N-aryl terminus to an α-imino amide intermediate, which the C-terminal hydrazide captures intramolecularly to close the ring as a stable keto-hydrazone in a single step.

Analogs of the antimicrobial peptide Gramicidin S and the integrin receptor ligand RGDfK were prepared using the method, extending its reach toward bioactive scaffolds. By establishing a mild, one-pot oxidative macrocyclization that accommodates diverse sequences and ring sizes of 16 to 25 atoms, the work offers the peptide community a practical route to hydrazone-bridged libraries for future therapeutic and structural studies.


Author

Karlee McKinney holds a B.Sc. in Chemistry and Exercise Science from Belhaven University. She is currently a fifth-year Ph.D. candidate in the Proulx lab at North Carolina State University, where she develops synthetic methods to access N-aryl peptides and leverages their unique reactivity for peptide cyclization and peptide-to-peptide ligation.

Author

Dr. Quibria Guthrie holds a Ph.D. in Chemistry from North Carolina State University and a B.S. in Chemistry from the University of Wisconsin–Milwaukee. Her doctoral research, conducted under the supervision of Dr. Caroline Proulx, focused on developing new approaches for the selective ligation of peptides. Following her doctoral studies, she joined CEM Corporation as a Research Scientist, where she contributed to the development of automated peptide synthesis technologies. She has since transitioned into the pharmaceutical industry, where she currently serves as a Process Chemist at Eli Lilly and Company. In her current role, she draws on her background in peptide chemistry to support process optimization and scale-up for peptide-based therapeutics.

Author

Briley Humphrey is a Ph.D. candidate at the Moffitt Cancer Center working under the advisement of Dr. Nicholas Lawrence. She completed undergraduate research in the Proulx lab and graduated in 2021 with a B.S. in chemistry from NC State University. Her current research focuses on the development of degraders, inhibitors, and covalent modifiers of understudied kinases in cancer.

Closing the Ring

Author

Dr. Ellen Warner is from Trinidad and Tobago. She received her B. Sc. in Chemistry from Davidson College and her Ph.D. from North Carolina State University in 2025, working on the cyclization of N-aryl peptide hydrazides under the guidance of Prof. Caroline Proulx. In 2024, Ellen completed an internship at Eli Lilly working in the Biotechnology Discovery Research, BioTDR, Peptide group and Synthetic Molecule Design and Development, SMDD, group. She currently lives in Canberra, Australia and misses making peptides!